I wish I could access the full text article, but all I can comment on is the abstract. Everything is the abstract sounds fine except for the parts you pointed out Golfyeti:

"Re-conceptualizing cardiovascular disease within the well-established evolutionary biology theory that growth and specifically reproduction trade-off against longevity might provide a more comprehensive explanation."

Hmmmmm. I think they are just pointing out that as we all age, our fertility declines. Evolutionarily this makes sense. Breed while you are young and strong, not when you are old and weak and succumbing to chronic illnesses. Survivial of the fittest......

"Drivers of the gonadotropic axis, particularly androgens, suppress both HDL-C and the immune system while promoting ischemic heart disease and stroke."

In general, men have higher risk of cardiovascular disease than women. This is in part due to estrogen having many cardiometabolic protective effects and androgens (i.e. testoterone) being less cardioprotective or even increasing cardiometabolic risk (i.e. lowering HDL-C). Both men and women have both testosterone and estrogen. In fact, there is just a single enzymatic reaction that separates the two hormones. CYP19A1 aka aromatase enzyme converts testosterone to estrogen. Fun fact of the day! Of course, estrogen levels are MUCH higher in women than men, and conversely androgen levels are MUCH lower in women than men. Keep in mind estrogen levels plummet in women going through the menopausal transition. This drop in estrogen is hypothesized to increase cardiometabolic risk in menopausal women.

"As such, any effects of RVX-208 on cardiovascular disease might be the result of reducing androgens, of which higher HDL-C and reduced inflammation are biomarkers."

Say what? I have no idea where they are getting the idea of apabetalone/RVX-208 reducing androgens or having any documented effect on steroid hormone biology. This is where having the full text of the article would be helpful to see what data and references they use to back this claim up. As far as I know Resverlogix has never used apabetalone or RVX-208 in the same sentence as androgens. Take that above sentence from the abstract with a large grain of salt. Pinocchio alert!

"Notably, several other effective treatments for cardiovascular disease, such as statins and spironolactone, are known anti-androgens."

Hmmmm. Partial Pinocchio on this one. Spironolactone is a well documented anti-androgen. I've never heard it being promoted as an effective treatment for cardiovascular disease though. Statins ARE NOT, let me repeat, ARE NOT anti-androgens. Statins inhibit the rate limiting step in cholesterol biosynthesis, which is the production of mevalonate by HMG-CoA reductase. Cells can get their cholesterol via biosynthesis or cellular uptake. Nobel prize winning research by Joseph Goldstein and Michael Brown initially characterized the uptake pathway by which cells, via LDL receptors, can endocytose (take into the cell) LDL lipoproteins bound to the cell surface LDL receptors. So even in cells in which HMG-CoA reductase is inhibited by statins, these cells can get cholesterol by taking in LDL from the blood. This is why statins lower LDL-C! Cholesterol is a precursor for the synthesis of steroid hormones, including androgens. However, cholesterol is never limiting for androgen production. Plus, I have never heard of statins interfering in any way with androgens binding to the androgen receptor. Big 'ol Pinocchio on the statin anti-androgen claim.

BearDownAZ